Sildenafil
Treatment for Pulmonary Arterial Hypertension
Typical Dosage: 20mg three times daily
Effectiveness
80%
Safety Score
60%
Clinical Trials
125
Participants
12K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
20mg three times daily
Time to Effect
Weeks to months
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
5(Treat 5 patients to see 1 additional successful outcome)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$2,000
Monitoring:$4,500
Side Effect Mgmt:$300
Total Annual:$6,800
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
0.2
Outcome-Based Costs
Cost per Responder
$17,000
Cost per Remission
$85,000
Sildenafil Outcomes
for Pulmonary Arterial Hypertension
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+40%
Remission Rate
+8%
Common Side Effects
Headache
+50%
Flushing
+25%
Dyspepsia
+18%
Nasal Congestion
+12%
Visual Disturbances
+10%
Active Clinical Trials
1 active trial recruiting for Sildenafil in Pulmonary Arterial Hypertension
Randomized Study of Triple Therapy vs Sildenafil Dose Optimization in Pulmonary Arterial Hypertension
NCT07713914RECRUITINGPHASE4
196 participants
INTERVENTIONAL
São Paulo, Brazil
Started: Jul 22, 2026
Completed Clinical Trials
10 completed trials for Sildenafil in Pulmonary Arterial Hypertension
Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial Hypertension
NCT01365585COMPLETED
227 participants
OBSERVATIONAL
Hanover, Germany +1 more
Started: Jul 1, 2011
Revatio Special Investigation for Long-term Use in Pediatric Patients
NCT03364244COMPLETED
1.02K participants
OBSERVATIONAL
Tokyo, Japan
Started: Nov 30, 2017
A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children
NCT00159874COMPLETEDPHASE3
234 participants
INTERVENTIONAL
Palo Alto, United States +38 more
Started: Jan 1, 2004
Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension
NCT01642407COMPLETEDPHASE4
6 participants
INTERVENTIONAL
Sagamihara, Japan +4 more
Started: Aug 24, 2012
Responsiveness of Exercise Tests in Pulmonary Arterial Hypertension
NCT01391104COMPLETEDNA
22 participants
INTERVENTIONAL
Québec, Canada
Started: Apr 1, 2009
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants
NCT01392469COMPLETEDPHASE3
21 participants
INTERVENTIONAL
Tampa, United States +10 more
Started: Apr 20, 2011
Combination Therapy in Pulmonary Arterial Hypertension
NCT00433329COMPLETEDPHASE4
100 participants
INTERVENTIONAL
Started: Mar 1, 2007
A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension.
NCT00159913COMPLETEDPHASE3
235 participants
INTERVENTIONAL
Palo Alto, United States +40 more
Started: Aug 1, 2003
Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Sildenafil
NCT04994860COMPLETEDPHASE1
20 participants
INTERVENTIONAL
Berlin, Germany
Started: Mar 22, 2018
Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)
NCT00617305COMPLETEDPHASE4
38 participants
INTERVENTIONAL
Mobile, United States +29 more
Started: Apr 1, 2008
Showing 20 of 128 total trials